Glaxo to top up Theravance stake
Drugs giant GlaxoSmithKline is to increase its stake in US biopharmaceutical company Theravance.
Drugs giant GlaxoSmithKline is to increase its stake in US biopharmaceutical company Theravance.
Theravance will issue 10m shares to Glaxo at $21.2887 per share, meaning the UK company will spend $212.9m to up its stake in Theravance from 18.3% to 26.8%.
The price per share was a 7.5% premium to the average price per share of Theravance common stock over the five-day period ending March 30, which was $19.8034.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The two companies have been collaborating since 2002 on drugs development, including work on Relovair, seen as a successor to Glaxo's top-selling inhaled lung treatment Advair.
Relovair has now completed its Phase III development and Glaxo intends to submit regulatory applications for chronic obstructive pulmonary disease in the US and Europe in mid-2012.
For the treatment of asthma using Relovair, Glaxo also plans to submit an application in Europe in mid-2012 and will continue discussions with the US Food and Drug Administraton on the regulatory requirements for a US asthma indication.
NR/JH
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
8 of the best houses for sale with annexes
The best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
By Natasha Langan Published
-
Zelenskyy moves to appease Donald Trump – what happens now?
Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
By Emily Hohler Published